S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Aeterna Zentaris Stock Forecast, Price & News

+0.04 (+5.49 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $0.77
50-Day Range
MA: $0.48
52-Week Range
Now: $0.77
Volume10.57 million shs
Average Volume11.37 million shs
Market Capitalization$48.20 million
P/E RatioN/A
Dividend YieldN/A
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Aeterna Zentaris logo


Overall MarketRank

0.58 out of 5 stars

Medical Sector

1331st out of 1,926 stocks

Pharmaceutical Preparations Industry

593rd out of 773 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AEZS



Sales & Book Value

Annual Sales$530,000.00
Book Value($0.12) per share


Net Income$-6,040,000.00
Net Margins-369.10%


Market Cap$48.20 million
Next Earnings Date3/29/2021 (Estimated)
+0.04 (+5.49 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aeterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

How has Aeterna Zentaris' stock price been impacted by COVID-19 (Coronavirus)?

Aeterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AEZS stock has increased by 13.2% and is now trading at $0.7690.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Aeterna Zentaris?

Wall Street analysts have given Aeterna Zentaris a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aeterna Zentaris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Aeterna Zentaris' CEO?

1,448 employees have rated Aeterna Zentaris CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Aeterna Zentaris' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Aeterna Zentaris' next earnings date?

Aeterna Zentaris is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Aeterna Zentaris

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.13 million during the quarter. Aeterna Zentaris had a negative return on equity of 125.54% and a negative net margin of 369.10%.
View Aeterna Zentaris' earnings history

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,890,000 shares, an increase of 28.6% from the December 15th total of 1,470,000 shares. Based on an average daily trading volume, of 2,130,000 shares, the short-interest ratio is currently 0.9 days. Currently, 3.2% of the company's shares are sold short.
View Aeterna Zentaris' Short Interest

Who are some of Aeterna Zentaris' key competitors?

What other stocks do shareholders of Aeterna Zentaris own?

Who are Aeterna Zentaris' key executives?

Aeterna Zentaris' management team includes the following people:
  • Dr. Klaus Paulini Ph.D., Pres, CEO & Director
  • Ms. Leslie Auld C.A., CPA, M.B.A., MBA, CPA, CA, Sr. VP & CFO
  • Dr. Nicola Ammer M.D., Chief Medical Officer & VP of Clinical Devel.
  • Dr. Matthias Gerlach, VP of Manufacturing & Supply Chain
  • Mr. Olaf Althaus, GM & MD
  • Dr. Eckhard G. Guenther Ph.D., VP of Bus. Devel. & Alliance Management and Managing Director AEZS Germany
  • Ms. Amélie Métivier, Assistant Sec.

What is Aeterna Zentaris' stock symbol?

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How do I buy shares of Aeterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aeterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $0.77.

How big of a company is Aeterna Zentaris?

Aeterna Zentaris has a market capitalization of $48.20 million and generates $530,000.00 in revenue each year.

What is Aeterna Zentaris' official website?

The official website for Aeterna Zentaris is www.zentaris.com.

How can I contact Aeterna Zentaris?

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 49-6942-6020 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.